{I-bank focus}CCB starts Biostar Pharm (02563) at HKD35.85

  CCB initiates coverage of Biostar Pharm (02563) with a target price of HKD35.85 and an "outperform" rating.
  The research house said a likely catalyst for Biostar Pharma is the potential approval of its oral formulation of Utidelone for the China market by end-4Q25F.